ClinicalTrials.gg
CompletedNCT01925768Updated May 12, 2020Results posted

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

A Phase 3 interventional study of Apremilast 30 mg and Placebo in Psoriatic Arthritis, sponsored by Amgen. Completed at 71 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-12.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.

Enrollment
9th of 17
219 · median 219
Started
2013
with 1 other
Phase 3
8 of 17
1 open now
Registered
8th of 17
by date
Lead sponsor
11 of 17
Amgen

Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 9th largest by enrollment, is one of 2 that started in 2013, is one of 8 in phase 3, and was the 8th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing apremilast in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.

Read the detailed description

This is a Phase 3b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast monotherapy in subjects with active psoriatic arthritis.

Approximately 214 subjects will be randomized in a 1:1 ratio to either apremilast 30 mg BID (twice a day) or identically-appearing placebo, with approximately 107 subjects per treatment group.

This is a 113-week study. The subjects will spend 24 weeks in the double-blind, placebo-controlled treatment phase, followed by 28 weeks of active treatment phase (ie, up to Week 52 visit). The original treatment assignments (apremilast 30 mg BID (twice a day) or placebo) will remain blinded until all subjects have completed their Week 52 visit (or have discontinued). After the Week 52 visit, all subjects in the extension phase will continue to receive treatment with apremilast 30 mg BID (twice a day) until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.

The study will consist of 5 phases:

  1. Screening Phase - up to 5 weeks
  2. Randomized, Placebo-controlled, Double Blind Treatment Phase - Weeks 0 to 24
  3. Active Treatment Phase - Week 24 to Week 52
  4. Open-label Extension Phase - Week 52 to Week 104
  5. Post-treatment Observational Follow-up Phase
03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Apremilast, Psoriatic Arthritis, PDE4 inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, 18 years and older at time of consent.
  2. Must understand and voluntarily sign an document prior to any study related assessments/procedures being conducted.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Have a documented diagnosis of psoriatic arthritis (by any criteria) of at least 3 months' duration
  5. Meet the classification criteria for psoriatic arthritis (CASPAR) at the time of screening.
  6. Have at least 3 swollen AND at least 3 tender joints.
  7. Must have high sensitivity C-Reactive Protein (hs-CRP) of at least 0.5 mg/dL at screening and at baseline.
  8. Must be receiving treatment on an outpatient basis.
  9. Must be tumor necrosis factor (TNF) blocker naive and other Biologic naïve for dermatologic and rheumatic conditions
  10. Subjects taking disease modifying anti-rheumatoid drugs (DMARDs), with the exception of cyclosporine and leflunomide (see 7.3. Exclusion Criteria 20, 21), do not require a , however, they must discontinue the DMARD treatment at least one day prior to their baseline visit (ie, Visit 2, Day 0)
  11. Subjects who have been previously treated with leflunomide will require a 12-week washout or treatment with the cholestyramine, per leflunomide prescribing label (ie. 8 g cholestyramine 3 times daily for 11 days.
  12. Subjects who have been previously treated with cyclosporine will require a 4-week washout prior to randomization to participate in the study
  13. If taking oral , must be on a stable dose of prednisone less than or equal to 10 mg/day or equivalent for at least 30 days prior to baseline visit (ie, Day 0)
  14. If taking nonsteroidal anti-inflammatory drugs (NSAIDs) or narcotic analgesics, must be on stable dose for at least 30 days prior to baseline visit (ie, Day 0) and until they have completed the Week 24 study visit.
  15. Must meet the following laboratory criteria:

    • White blood cell count greater than 3000/mm\^3 (greater than 3.0 X 10\^9/L) and less than 14,000/mm\^3 (less than 14 X 10\^9/L)
    • count at least 100,000/mm\^3 (at least 100 X 10\^9/L)
    • Serum creatinine less than or equal to 1.5 mg/dL (less than or equal to 132.6 μmol/L)
    • (AST) and alanine aminotransferase (ALT) less than or equal to twice (ULN). If initial test shows ALT or AST greater than 2 times the ULN, one repeat test is allowed during the screening period.
    • Total less than or equal to 2 mg/dL (less than or equal to 34 μmol/L) or Albumin greater than LLN. If initial test result is greater than 2 mg/dL, one repeat test is allowed during the screening period.
    • at least 9 g/dL (at least 5.6 mmol/L)
    • less than or equal to 9.0%
  16. All females of (FCBP) must use one of the approved options as described below while on product and for at least 28 days after administration of the last dose of the investigational product.

    At the time of study entry, and at any time during the study when a female subject of childbearing potential's contraceptive measures or ability to become pregnant changes, the investigator will educate the subject regarding contraception options and the correct and consistent use of effective contraceptive methods in order to successfully prevent pregnancy.

    Females of childbearing potential must have a negative pregnancy test at Screening and Baseline. All FCBP subjects who engage in activity in which conception is possible must use one of the approved contraceptive options described below:

    Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or non latex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

  17. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (male latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) while on investigational product and for at least 28 days after the last dose of investigational product.

Exclusion criteria

Exclusion Criteria:

  1. History of (as determined by the investigator) cardiac, endocrine, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease.
  2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  3. Clinically significant abnormality on a 12-lead (ECG) at Screening.
  4. Pregnant or breast feeding.
  5. History of allergy to any component of the product.
  6. surface antigen positive at screening.
  7. antibody positive at screening.
  8. History of positive (HIV), or congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency Disease).
  9. Active tuberculosis or a history of incompletely treated tuberculosis.
  10. Clinically significant abnormality based upon chest radiograph with at least posterior-anterior (PA) view (the radiograph must be taken within 12 weeks prior to Screening or during the Screening visit). An additional lateral view is strongly recommended but not required.
  11. Active substance abuse or a history of substance abuse within 6 months prior to Screening.
  12. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed and the infection cured, at least 4 weeks prior to Screening.
  13. or history of malignancy, except for:

    1. treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;
    2. treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years.
  14. Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
  15. Erythrodermic, guttate, or generalized pustular psoriasis at randomization.
  16. Rheumatic disease other than PsA, including, but not limited to: systemic lupus erythematosis (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis, or fibromyalgia.
  17. Functional Class IV, as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.
  18. Prior history of or current inflammatory joint disease other than PsA (eg, gout, reactive arthritis, rheumatoid arthritis (RA), ankylosing spondylitis, Lyme disease).
  19. Prior treatment with more than one non-biologic DMARD
  20. Use of the following systemic therapy(ies) within 4 weeks of randomization: cyclosporine or other calcineurin inhibitors, exceeding 10 mg daily prednisone equivalent, as well as other oral agents such as retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, tacrolimus.
  21. Use of leflunomide within 12 weeks of randomization, unless subject has taken cholestyramine, 8g TID (three times a day) x 11 days after stopping leflunomide.
  22. Previous treatment with biologic agents for rheumatic diseases such as, but not limited to: adalimumab, abatacept, canakinumab, etanercept, golimumab, infliximab, rilonacept, certolizumab pegol, or tocilizumab.
  23. Previous treatment with biologic agents for dermatologic diseases such as alefacept, anti-TNFs (eg etanercept, adalinumab) or ustekinumab.
  24. Previous treatment with tofacitinib, Anti IL-17 agents or secukinumab
  25. Previous treatment with any cell depleting therapies, including investigational agents (eg, rituximab, alemtuzumab, ocrelizumab, alemtuzumab, anti-CD4, anti-CD5, anti-CD3, anti-CD19, and anti-CD20).
  26. Treatment with intravenous gamma globulin, plasmapheresis, or Prosorba® column
  27. Any previous treatment with alkylating agents such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation.
  28. Prior treatment with any non-biologic DMARDS other than methotrexate, sulfasalazine, chloroquine, hydroxychloroquine, azathioprine, fumeric acid esters, cyclosporine, or leflunomide
  29. Prior treatment with apremilast, or participation in a clinical study, involving apremilast
  30. Use of any investigational drug within 4 weeks of randomization, or 5 pharmacokinetic/ pharmacodynamic half lives, if known (whichever is longer).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    Apremilast 30 mg

    30 mg Apremilast tablets administered twice daily (BID) for 24 weeks during the double-blind placebo-controlled phase; followed by 30 mg Apremilast BID for 28 weeks of active treatment phase (up to the 52 week visit); original treatment assignments remain blinded until all participants have completed their 52 week visit or have discontinued. After the Wk 52 visit, all participants in the extension phase will continue to receive treatment with apremilast 30 mg BID until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.

    Drug: Apremilast 30 mg

  • Placebo comparator
    Placebo

    Oral placebo BID during the placebo controlled phase weeks 0 to 24; placebo treated participants whose improvement is \<10% in both swollen and tender joint counts at Week 16 are eligible for early escape (based on the measure of clinical benefit from their current treatment as evidenced by improvement (or lack of improvement) in 1) the physician (evaluator's) global assessment (EGA), 2) patients pain (pain NRS), 3) the patient global assessments (PGA), and 4) the health assessment questionnaire disability index (HAQ-DI); Placebo-treated patients who early escape are transitioned to apremilast 30 mg PO BID during the active treatment phase up to their Week 52 visit; all those who complete the 52-week treatment phase will enter an open-label extension phase for an additional 52 weeks or until early discontinuation from the trial.

    Drug: Placebo

Interventions

  • 30mg of Apremilast will be orally administered twice daily for 104 weeks

    Also known as: Otezla, CC-10004

  • DrugPlacebo

    Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 16

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale \[NRS\]); * Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS); * Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * C-Reactive Protein (CRP) Those who withdrew early or who did not have sufficient data at Week 16 were counted as non-responders.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24

    HAQ-DI is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A higher score indicates worse physical functioning, and a negative change from baseline indicates improvement.

    Time frame: Baseline and Week 24

  2. Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) at Week 24

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale \[NRS\]); * Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS); * Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * C-Reactive Protein (CRP) Those who withdrew early or who did not have sufficient data at Week 16 were counted as non-responders.

    Time frame: Baseline and Week 24

  3. Change From Baseline in the 28-Joint Disease Activity Score Using C-reactive Protein as the Acute-Phase Reactant (DAS28 [CRP]) at Week 24

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: * 28 tender joint count * 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; * C-reactive protein (CRP) * Patient's global assessment of disease activity. DAS28 (CRP) scores range from 0 to 9.4. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. A higher value indicates higher disease activity, and a negative change from baseline indicates improvement.

    Time frame: Baseline and Week 24

  4. Change From Baseline in the Medical Outcomes Short Form Health Survey (SF-36) V2 Physical Function Domain Score at Week 24

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 24

  5. Change From Baseline in the 36-item SF-36 Physical Component Summary Score at Week 24

    The SF-36 (v 2.0) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary (PCS) score includes the physical functioning, role physical, bodily pain, and general health domains. Minimum clinically important difference (MCID) for the scale scores, as well as the PCS and MCS, is defined as a 2.5-point improvement (increase) from baseline. The summary scores range from 0 to 100, with lower scores reflecting more disability, and higher scores reflecting less disability and better health. The 8 domains are regrouped into the PCS and MCS scores.

    Time frame: Baseline and Week 24

  6. Change From Baseline in the Duration of Morning Stiffness at Week 24

    Morning stiffness was the participant's assessment of how long their morning stiffness lasted after first waking up in the morning, on average, during the previous week. A higher value indicates longer duration, and a negative change from baseline indicates improvement.

    Time frame: Baseline and Week 24

  7. Percentage of Participants With Improved Change in Severity of Morning Stiffness at Week 24

    Morning stiffness severity was the participant's assessment of how severe their morning stiffness was after first waking up in the morning, on average, during the previous week. The severity was recorded as none, mild, moderate, moderately severe, or very severe. The response of no improvement includes subjects who had no change or worsened. Improvement is defined as the change from baseline of a more severe assessment to less severe assessment.

    Time frame: Baseline and Week 24

  8. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16

    HAQ-DI is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A higher score indicates worse physical functioning, and a negative change from baseline indicates improvement.

    Time frame: Baseline and Week 16

  9. Change From Baseline in the Disease Activity Score DAS28 (CRP) at Week 16

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: * 28 tender joint count * 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; * C-reactive protein (CRP) * Patient's global assessment of disease activity. DAS28 (CRP) scores range from 0 to 9.4. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 16

  10. Change From Baseline in 36-item Short Form Health Survey (SF-36) V 2 Physical Functioning Domain at Week 16

    The SF-36 (v 2.0) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 16

  11. Mean Change From Baseline in the Duration of Morning Stiffness at Week 16

    Morning stiffness was the participant's assessment of how long their morning stiffness lasted after first waking up in the morning, on average, during the previous week. A higher value indicates longer duration, and a negative change from baseline indicates improvement.

    Time frame: Baseline and Week 16

  12. Percentage of Participants Whose Severity of Morning Stiffness at Week 16 Improved From Baseline

    Morning stiffness severity was the participant's assessment of how severe their morning stiffness was after first waking up in the morning, on average, during the previous week. The severity was recorded as none, mild, moderate, moderately severe, or very severe. Improvement is defined as the change from baseline of a more severe assessment to less severe assessment. Full Analysis Set; Participants who discontinued early prior to Week 16 and those who did not have sufficient data for a definitive determination of response status at Week 16 were counted as non-responders.

    Time frame: Baseline and Week 16

  13. Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4, 6, 8, 12 and 20

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale \[NRS\]); * Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS); * Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * C-Reactive Protein (CRP)

    Time frame: Baseline and at Weeks 2, 4, 6, 8, 12 and 20

  14. Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Weeks 52 and 104

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale \[NRS\]); * Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS); * Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * C-Reactive Protein (CRP)

    Time frame: Baseline and Weeks 52 and 104

  15. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 52 and 104

    HAQ-DI is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A higher score indicates worse physical functioning, and a negative change from baseline indicates improvement.

    Time frame: Baseline and Weeks 52 and 104

  16. Change From Baseline in the Disease Activity Score (DAS28) at Week 52 and 104

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: * 28 tender joint count * 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; * C-reactive protein (CRP) * Patient's global assessment of disease activity. DAS28 (CRP) scores range from 0 to 9.4. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. A negative change from baseline indicates improvement.

    Time frame: Baseline and Weeks 52 and 104

  17. Change From Baseline in 36-item SF-36 (V2.0) Physical Functioning Domain Score at Weeks 52 and 104

    The SF-36 (v 2.0) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Weeks 52 and 104

  18. Change From Baseline in the Duration of Morning Stiffness at Weeks 52 and 104

    Morning stiffness was the participant's assessment of how long their morning stiffness lasted after first waking up in the morning, on average, during the previous week. A higher value indicates longer duration, and a negative change from baseline indicates improvement.

    Time frame: Baseline and Weeks 52 and 104

  19. Percentage of Participants Whose Severity of Morning Stiffness at Week 52 and 104 Improved From Baseline

    Morning stiffness severity was the participant's assessment of how severe their morning stiffness was after first waking up in the morning, on average, during the previous week. The severity was recorded as none, mild, moderate, moderately severe, or very severe. Improvement is defined as the change from baseline of a more severe assessment to less severe assessment.

    Time frame: Baseline and Weeks 52 and 104

  20. Number of Participants With Treatment Emergent Adverse Events (TEAE) During the 24 Week Placebo Controlled Phase

    A TEAE is an AE with a start date on or after the date of the first dose of Investigational Product (IP). An AE is any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

    Time frame: Date of first dose of study drug to Week 24; median duration of exposure during placebo controlled phase was 24.14 weeks

  21. Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-Exposure Period

    A TEAE is an AE with a start date on or after the date of the first dose of Investigational Product (IP). An AE is any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

    Time frame: Start of lst dose of IP up to week 104: Weeks 0 to104 for those initially randomized to APR 30 mg BID, Weeks 16 -104 for PBO-treated patients who EE to APR at Week 16 and from Weeks 24-104 for PBO-treated patients who transitioned to APR at Week 24

07

Results

Posted Jun 13, 2016

Participant flow

The study consisted of a 24-week randomized, double-blind, placebo-controlled treatment phase, followed by a 28-week active treatment phase and a 52-week open-label extension phase, for an overall study duration of 113 weeks. 219 subjects were enrolled from 59 centers across 10 countries.

Placebo-controlled Phase (Week 0 - 24)
Participant flow — Placebo-controlled Phase (Week 0 - 24)
MilestonePlacebo/Apremilast (PBO)Apremilast (APR)
Started109110
Received treatment109109
Completed week 1610191
Escaped early (ee)3513
Completed9887
Not completed1123
Withdrew: Lost to follow-up10
Withdrew: Protocol violation12
Withdrew: Adverse event510
Withdrew: Lack of efficacy36
Withdrew: Withdrawal by subject14
Withdrew: Non-compliance with study drug01
ActiveTreatment/Extension (Weeks 24-104)
Participant flow — ActiveTreatment/Extension (Weeks 24-104)
MilestonePlacebo/Apremilast (PBO)Apremilast (APR)
Started9585
Completed7567
Not completed2018
Withdrew: Lack of efficacy66
Withdrew: Withdrawal by subject79
Withdrew: Lost to follow-up21
Withdrew: Death01
Withdrew: Adverse event51

Outcome measures

PrimaryPercentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 16

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale \[NRS\]); * Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS); * Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * C-Reactive Protein (CRP) Those who withdrew early or who did not have sufficient data at Week 16 were counted as non-responders.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 16
percentage of participantsPlacebo (PBO)Apremilast (APR) 30 mg
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 1620.238.2
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Cochran-Mantel-Haenszel · p = 0.0040 (Two-sided p-value is based on the Cochran-Mantel-Haenszel test adjusting for previous DMARD use and baseline Oral Corticosteroids (Prednisone or equivalent) use.) · Adjusted difference: 17.7 · 95% CI 6.2 to 29.3Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by the 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights. The CI is based on a normal approximation.
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24

HAQ-DI is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A higher score indicates worse physical functioning, and a negative change from baseline indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24
units on a scalePlacebo (PBO)Apremilast (APR) 30 mg
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24-0.169 ± 0.0581-0.273 ± 0.0572
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Mixed Models Analysis · p = 0.1677 · Ls mean difference: -0.103 · 95% CI -0.251 to 0.044The LS mean (SE) and 2-sided p-value were based on a MMRM analysis for change from baseline, with treatment group, time, treatment-by-time interaction, and previous DMARD and baseline corticosteroids used as factors and baseline value as a covariate
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) at Week 24

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale \[NRS\]); * Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS); * Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * C-Reactive Protein (CRP) Those who withdrew early or who did not have sufficient data at Week 16 were counted as non-responders.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) at Week 24
percentage of participantsPlacebo (PBO)Apremilast (APR) 30 mg
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) at Week 2424.843.6
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Cochran-Mantel-Haenszel · p = 0.0040 (Two-sided p-value is based on the Cochran-Mantel-Haenszel test adjusting for previous DMARD use and baseline Oral Corticosteroids (Prednisone or equivalent) use.) · Adjusted difference: 18.5 · 95% CI 6.3 to 30.6Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by the 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights. The CI is based on a normal approximation.
SecondaryChange From Baseline in the 28-Joint Disease Activity Score Using C-reactive Protein as the Acute-Phase Reactant (DAS28 [CRP]) at Week 24

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: * 28 tender joint count * 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; * C-reactive protein (CRP) * Patient's global assessment of disease activity. DAS28 (CRP) scores range from 0 to 9.4. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. A higher value indicates higher disease activity, and a negative change from baseline indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the 28-Joint Disease Activity Score Using C-reactive Protein as the Acute-Phase Reactant (DAS28 [CRP]) at Week 24
units on a scalePlacebo (PBO)Apremilast (APR) 30 mg
Change From Baseline in the 28-Joint Disease Activity Score Using C-reactive Protein as the Acute-Phase Reactant (DAS28 [CRP]) at Week 24-0.76 ± 0.140-1.26 ± 0.138
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Mixed Models Analysis · p = 0.0051 · Ls mean difference: -0.50 · 95% CI -0.85 to -0.15The LS mean (SE) and 2-sided p-value were based on a MMRM analysis for change from baseline, with treatment group, time, treatment-by-time interaction, and previous DMARD and baseline corticosteroids used as factors and baseline value as a covariate.
SecondaryChange From Baseline in the Medical Outcomes Short Form Health Survey (SF-36) V2 Physical Function Domain Score at Week 24

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Medical Outcomes Short Form Health Survey (SF-36) V2 Physical Function Domain Score at Week 24
units on a scalePlacebo (PBO)Apremilast (APR) 30 mg
Change From Baseline in the Medical Outcomes Short Form Health Survey (SF-36) V2 Physical Function Domain Score at Week 241.26 ± 0.9083.94 ± 0.888
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Mixed Models Analysis · p = 0.0167 · Ls mean difference: 2.68 · 95% CI 0.49 to 4.88The LS mean (SE) and 2-sided p-value were based on a MMRM analysis for change from baseline, with treatment group, time, treatment-by-time interaction, and previous DMARD and baseline corticosteroids used as factors and baseline value as a covariate
SecondaryChange From Baseline in the 36-item SF-36 Physical Component Summary Score at Week 24

The SF-36 (v 2.0) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The physical component summary (PCS) score includes the physical functioning, role physical, bodily pain, and general health domains. Minimum clinically important difference (MCID) for the scale scores, as well as the PCS and MCS, is defined as a 2.5-point improvement (increase) from baseline. The summary scores range from 0 to 100, with lower scores reflecting more disability, and higher scores reflecting less disability and better health. The 8 domains are regrouped into the PCS and MCS scores.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the 36-item SF-36 Physical Component Summary Score at Week 24
units on a scalePlacebo (PBO)Apremilast (APR) 30 mg
Change From Baseline in the 36-item SF-36 Physical Component Summary Score at Week 241.60 ± 0.9595.00 ± 0.949
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Mixed Models Analysis · p = 0.0039 (Based on an MMRM model for the change from baseline, with treatment group, time, treatment-by-time interaction, and previous DMARD use and baseline Oral Corticosteroids use as factors and the baseline value as a covariate.) · Ls mean difference: 3.40 · 95% CI 1.10 to 5.70
SecondaryChange From Baseline in the Duration of Morning Stiffness at Week 24

Morning stiffness was the participant's assessment of how long their morning stiffness lasted after first waking up in the morning, on average, during the previous week. A higher value indicates longer duration, and a negative change from baseline indicates improvement.

Time frame:
Baseline and Week 24
Reported as:
Mean · minutes
Change From Baseline in the Duration of Morning Stiffness at Week 24
minutesPlacebo (PBO)Apremilast (APR) 30 mg
Change From Baseline in the Duration of Morning Stiffness at Week 2421.9 ± 137.11-5.7 ± 83.41
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Sign test · p = 0.012 · Mean difference (final values): -10.0 · 95% CI -21.5 to 10.2p-value based on distribution free signed rank test
SecondaryPercentage of Participants With Improved Change in Severity of Morning Stiffness at Week 24

Morning stiffness severity was the participant's assessment of how severe their morning stiffness was after first waking up in the morning, on average, during the previous week. The severity was recorded as none, mild, moderate, moderately severe, or very severe. The response of no improvement includes subjects who had no change or worsened. Improvement is defined as the change from baseline of a more severe assessment to less severe assessment.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Improved Change in Severity of Morning Stiffness at Week 24
percentage of participantsPlacebo (PBO)Apremilast (APR)
Percentage of Participants With Improved Change in Severity of Morning Stiffness at Week 2420.240.0
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) · Cochran-Mantel-Haenszel · p = 0.0016 (Two-sided p-value is based on the Cochran-Mantel-Haenszel test adjusting for previous DMARD use and baseline oral corticosteroids (prednisone or equivalent) use.) · Adjusted difference: 19.7 · 95% CI 8.0 to 31.3Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by the 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights. The CI is based on a normal approximation.
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16

HAQ-DI is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A higher score indicates worse physical functioning, and a negative change from baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16
units on a scalePlacebo (PBO)Apremilast (APR) 30 mg
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 16-0.055 ± 0.0513-0.205 ± 0.0523
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Mixed Models Analysis · p = 0.0229 · Ls mean difference: -0.150 · 95% CI -0.279 to -0.021The LS mean (SE) and 2-sided p-value were based on a MMRM analysis for change from baseline, with treatment group, time, treatment-by-time interaction, and previous DMARD and baseline corticosteroids used as factors and baseline value as a covariate
SecondaryChange From Baseline in the Disease Activity Score DAS28 (CRP) at Week 16

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: * 28 tender joint count * 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; * C-reactive protein (CRP) * Patient's global assessment of disease activity. DAS28 (CRP) scores range from 0 to 9.4. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disease Activity Score DAS28 (CRP) at Week 16
units on a scalePlacebo (PBO)Apremilast (APR) 30 mg
Change From Baseline in the Disease Activity Score DAS28 (CRP) at Week 16-0.39 ± 0.129-1.07 ± 0.133
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Mixed Models Analysis · p = <0.0001 · Ls mean difference: -0.68 · 95% CI -1.00 to -0.35The LS mean (SE) and 2-sided p-value were based on a MMRM analysis for change from baseline, with treatment group, time, treatment-by-time interaction, and previous DMARD and baseline corticosteroids used as factors and baseline value as a covariate
SecondaryChange From Baseline in 36-item Short Form Health Survey (SF-36) V 2 Physical Functioning Domain at Week 16

The SF-36 (v 2.0) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-item Short Form Health Survey (SF-36) V 2 Physical Functioning Domain at Week 16
units on a scalePlacebo (PBO)Apremilast (APR) 30 mg
Change From Baseline in 36-item Short Form Health Survey (SF-36) V 2 Physical Functioning Domain at Week 16-1.04 ± 0.9272.43 ± 0.962
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Mixed Models Analysis · p = 0.0039 · Ls mean difference: 3.46 · 95% CI 1.13 to 5.80Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by the 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights
SecondaryMean Change From Baseline in the Duration of Morning Stiffness at Week 16

Morning stiffness was the participant's assessment of how long their morning stiffness lasted after first waking up in the morning, on average, during the previous week. A higher value indicates longer duration, and a negative change from baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Mean · minutes
Mean Change From Baseline in the Duration of Morning Stiffness at Week 16
minutesPlacebo (PBO)Apremilast (APR) 30 mg
Mean Change From Baseline in the Duration of Morning Stiffness at Week 1621.7 ± 136.85-7.2 ± 60.73
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Stratified Van Elteren test · p = 0.0168 · Hodges-lehmann: 10.0 · 95% CI 0.0 to 20.0Location shift and 95% CI based on Hodges-Lehmann for between treatment median estimates.
SecondaryPercentage of Participants Whose Severity of Morning Stiffness at Week 16 Improved From Baseline

Morning stiffness severity was the participant's assessment of how severe their morning stiffness was after first waking up in the morning, on average, during the previous week. The severity was recorded as none, mild, moderate, moderately severe, or very severe. Improvement is defined as the change from baseline of a more severe assessment to less severe assessment. Full Analysis Set; Participants who discontinued early prior to Week 16 and those who did not have sufficient data for a definitive determination of response status at Week 16 were counted as non-responders.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Whose Severity of Morning Stiffness at Week 16 Improved From Baseline
percentage of participantsPlacebo (PBO)Apremilast (APR) 30 mg
Percentage of Participants Whose Severity of Morning Stiffness at Week 16 Improved From Baseline25.746.4
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Cochran-Mantel-Haenszel · p = 0.0015 (2 sided-p-value is based on the Cochran-Mantel-Haenszel test adjusting for previous DMARD use and baseline Oral Corticosteroids (Prednisone or equivalent) use.) · Adjusted difference: 20.7 · 95% CI 8.5 to 32.8Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by the 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4, 6, 8, 12 and 20

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale \[NRS\]); * Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS); * Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * C-Reactive Protein (CRP)

Time frame:
Baseline and at Weeks 2, 4, 6, 8, 12 and 20
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4, 6, 8, 12 and 20
percentage of participantsPlacebo (PBO)Apremilast (APR) 30 mg
Week 26.416.4
Week 415.624.5
Week 619.337.3
Week 822.936.4
Week 1228.440.0
Week 2024.843.6
Statistical analysis
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Cochran-Mantel-Haenszel · p = 0.0252 (Two-sided p-value is based on the Cochran-Mantel-Haenszel test adjusting for previous DMARD use and baseline Oral Corticosteroids (Prednisone or equivalent) use.) · Adjusted difference: 9.7 · 95% CI 1.6 to 17.7Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Cochran-Mantel-Haenszel · p = 0.1121 (Two-sided p-value is based on the Cochran-Mantel-Haenszel test adjusting for previous DMARD use and baseline Oral Corticosteroids (Prednisone or equivalent) use.) · Adjusted difference: 8.6 · 95% CI -1.7 to 18.9Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Cochran-Mantel-Haenszel · p = 0.0036 (Two-sided p-value is based on the Cochran-Mantel-Haenszel test adjusting for previous DMARD use and baseline Oral Corticosteroids (Prednisone or equivalent) use.) · Adjusted difference: 17.8 · 95% CI 6.2 to 29.3Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Cochran-Mantel-Haenszel · p = 0.0392 (Two-sided p-value is based on the Cochran-Mantel-Haenszel test adjusting for previous DMARD use and baseline Oral Corticosteroids (Prednisone or equivalent) use.) · Adjusted difference: 12.7 · 95% CI 0.8 to 24.6Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Cochran-Mantel-Haenszel · p = 0.0884 (Two-sided p-value is based on the Cochran-Mantel-Haenszel test adjusting for previous DMARD use and baseline Oral Corticosteroids (Prednisone or equivalent) use.) · Adjusted difference: 11.0 · 95% CI -1.3 to 23.2Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights
  • Placebo (PBO) vs Apremilast (APR) 30 mg · Cochran-Mantel-Haenszel · p = 0.0040 (Two-sided p-value is based on the Cochran-Mantel-Haenszel test adjusting for previous DMARD use and baseline Oral Corticosteroids (Prednisone or equivalent) use.) · Adjusted difference: 18.6 · 95% CI 6.5 to 30.7Adjusted difference in proportions is the weighted average of the treatment differences across 4 strata by 2 stratification factors: previous DMARD use and baseline Corticosteroids use using CMH weights
SecondaryPercentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Weeks 52 and 104

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: * ≥ 20% improvement in 78 tender joint count; * ≥ 20% improvement in 76 swollen joint count; and * ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's self-assessment of pain (measured on a 0 to 10 unit numeric rating scale \[NRS\]); * Patient's global self-assessment of disease activity (measured on a 0 to 10 unit NRS); * Physician's global assessment of disease activity (measured on a 0 to 10 unit NRS); * Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); * C-Reactive Protein (CRP)

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Number · percentage of partcipants
Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Weeks 52 and 104
percentage of partcipantsPlacebo/Apremilast (PBO-APR)Apremilast (APR)
Week 5260.0 (49.1 to 70.2)67.1 (55.6 to 77.3)
Week 10466.2 (54.3 to 76.8)59.4 (46.9 to 71.1)
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 52 and 104

HAQ-DI is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. A higher score indicates worse physical functioning, and a negative change from baseline indicates improvement.

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 52 and 104
units on a scalePlacebo/Apremilast (PBO-APR)Apremilast (APR)
Week 52-0.323 ± 0.5759-0.395 ± 0.5297
Week 104-0.382 ± 0.5639-0.357 ± 0.6102
SecondaryChange From Baseline in the Disease Activity Score (DAS28) at Week 52 and 104

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: * 28 tender joint count * 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; * C-reactive protein (CRP) * Patient's global assessment of disease activity. DAS28 (CRP) scores range from 0 to 9.4. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission. A negative change from baseline indicates improvement.

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Mean · units on a scale
Change From Baseline in the Disease Activity Score (DAS28) at Week 52 and 104
units on a scalePlacebo/Apremilast (PBO-APR)Apremilast (APR)
Week 52-1.46 ± 0.985-1.71 ± 1.054
Week 104-1.62 ± 1.086-1.70 ± 1.305
SecondaryChange From Baseline in 36-item SF-36 (V2.0) Physical Functioning Domain Score at Weeks 52 and 104

The SF-36 (v 2.0) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Mean · units on a scale
Change From Baseline in 36-item SF-36 (V2.0) Physical Functioning Domain Score at Weeks 52 and 104
units on a scalePlacebo/Apremilast (PBO-APR)Apremilast (APR)
Week 525.11 ± 9.8426.00 ± 9.990
Week 1045.78 ± 9.9325.95 ± 10.827
SecondaryChange From Baseline in the Duration of Morning Stiffness at Weeks 52 and 104

Morning stiffness was the participant's assessment of how long their morning stiffness lasted after first waking up in the morning, on average, during the previous week. A higher value indicates longer duration, and a negative change from baseline indicates improvement.

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Mean · minutes
Change From Baseline in the Duration of Morning Stiffness at Weeks 52 and 104
minutesPlacebo/Apremilast (PBO-APR)Apremilast (APR)
Week 523.3 ± 174.41-5.7 ± 93.62
Week 104-11.9 ± 165.36-7.0 ± 71.34
SecondaryPercentage of Participants Whose Severity of Morning Stiffness at Week 52 and 104 Improved From Baseline

Morning stiffness severity was the participant's assessment of how severe their morning stiffness was after first waking up in the morning, on average, during the previous week. The severity was recorded as none, mild, moderate, moderately severe, or very severe. Improvement is defined as the change from baseline of a more severe assessment to less severe assessment.

Time frame:
Baseline and Weeks 52 and 104
Reported as:
Number · percentage of participants
Percentage of Participants Whose Severity of Morning Stiffness at Week 52 and 104 Improved From Baseline
percentage of participantsPlacebo/Apremilast (PBO-APR)Apremilast (APR)
Week 5257.157.5
Week 10450.759.4
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) During the 24 Week Placebo Controlled Phase

A TEAE is an AE with a start date on or after the date of the first dose of Investigational Product (IP). An AE is any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

Time frame:
Date of first dose of study drug to Week 24; median duration of exposure during placebo controlled phase was 24.14 weeks
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the 24 Week Placebo Controlled Phase
ParticipantsPlacebo (PBO)Apremilast (APR) 30 mg
Any TEAE6973
Any drug-related TEAE1830
Any severe TEAE42
Any serious TEAE53
Any serious drug-related TEAE00
Any TEAE leading to study drug withdrawal510
Any TEAE leading to study dose interruption710
Any TEAE leading to death00
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-Exposure Period

A TEAE is an AE with a start date on or after the date of the first dose of Investigational Product (IP). An AE is any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.

Time frame:
Start of lst dose of IP up to week 104: Weeks 0 to104 for those initially randomized to APR 30 mg BID, Weeks 16 -104 for PBO-treated patients who EE to APR at Week 16 and from Weeks 24-104 for PBO-treated patients who transitioned to APR at Week 24
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-Exposure Period
ParticipantsApremilast (APR) 30 mg
Any TEAE157
Any drug-related TEAE52
Any severe TEAE8
Any serious TEAE15
Any serious drug-related TEAE0
Any TEAE leading to study dose interruption28
Any TEAE leading to study drug withdrawal17
Any TEAE leading to death1

Adverse events

Collected over AE's are reported: 1. Placebo-controlled phase (Weeks 0-24) 2. Up to 104 weeks for all participants randomized or transitioned onto apremilast at any time during the study (apremilast-exposure phase). AEs were monitored for 37 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Controlled Phase: Placebo (Weeks 0-24)—5/109 (4.6%)37/109 (33.9%)
Placebo-Controlled Phase: Apremilast (Weeks 0-24)—3/109 (2.8%)41/109 (37.6%)
APR Exposure Period: Apremilast—15/206 (7.3%)83/206 (40.3%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlacebo-Controlled Phase: Placebo (Weeks 0-24)Placebo-Controlled Phase: Apremilast (Weeks 0-24)APR Exposure Period: Apremilast
Coronary artery diseaseCardiac disorders0/1090/1092/206
Iron deficiency anaemiaBlood and lymphatic system disorders1/1090/1090/206
Angina pectorisCardiac disorders1/1090/1090/206
Chest painGeneral disorders1/1090/1090/206
Biliary colicHepatobiliary disorders0/1091/1091/206
Cervical vertebral fractureInjury, poisoning and procedural complications1/1090/1090/206
Head injuryInjury, poisoning and procedural complications0/1091/1091/206
Joint dislocationInjury, poisoning and procedural complications0/1091/1091/206
Spinal column injuryInjury, poisoning and procedural complications1/1090/1090/206
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1090/1090/206
Most frequent other events
Most frequent other events
EventPlacebo-Controlled Phase: Placebo (Weeks 0-24)Placebo-Controlled Phase: Apremilast (Weeks 0-24)APR Exposure Period: Apremilast
DiarrhoeaGastrointestinal disorders12/10916/10934/206
Upper respiratory tract infectionInfections and infestations11/1095/10917/206
NauseaGastrointestinal disorders2/1099/10918/206
NasopharyngitisInfections and infestations7/1099/10917/206
HeadacheNervous system disorders4/1098/10913/206
HypertensionVascular disorders7/1097/10913/206
BronchitisInfections and infestations3/1095/10911/206

Baseline characteristics

Full analysis set consisting of all participants who were randomized as specified in the protocol.

Age, Continuous
Age, Continuous(years)Placebo (PBO)Apremilast (APR) 30 mgTotal
Mean48.0 ± 13.7550.7 ± 12.2249.3 ± 13.04
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (PBO)Apremilast (APR) 30 mgTotal
Female6558123
Male445296
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo (PBO)Apremilast (APR) 30 mgTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander101
Black or African American101
White105109214
More than one race000
Unknown or Not Reported202
Duration of Psoriatic Arthritis
Duration of Psoriatic Arthritis(years)Placebo (PBO)Apremilast (APR) 30 mgTotal
Mean3.59 ± 5.4974.04 ± 4.4823.82 ± 5.007
08

Study locations

71 sites
  • Achieve Clinical Research LLC
    Birmingham, Alabama 35216, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Bay Area Arthritis and Osteoporosis
    Brandon, Florida 33511, United States
  • Health Point Medical Group
    Brandon, Florida 33511, United States
  • Palmetto Medical Research
    Hialeah, Florida 33016, United States
  • Jeffrey Alper MD Research
    Naples, Florida 34102, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • University of South Florida
    Tampa, Florida 33612-4799, United States
  • Coeur D'Alene Arthritis Clinic
    Coeur d'Alene, Idaho 83814, United States
  • Rockford Orthopedic Associates, LLC
    Rockford, Illinois 61107, United States
  • Advanced Rheumatology
    Lansing, Michigan 48910, United States
  • Research West Incorporated
    Kalispell, Montana 59901, United States
  • Heartland Clinical Research, Inc.
    Omaha, Nebraska 68134, United States
  • Physicians East
    Greenville, North Carolina 27834, United States
  • Piedmont Medical Research Associates Inc
    Winston-Salem, North Carolina 27103-3914, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Ramesh C Gupta MD
    Memphis, Tennessee 38119, United States
  • Austin Regional Clinic
    Austin, Texas 78731, United States
  • Baylor Research Institute
    Dallas, Texas 75231, United States
  • Houston Medical Research
    Houston, Texas 77090, United States
  • Arthritis and Osteoporosis Associates LLP
    Lubbock, Texas 79424, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Mountain State Clinical Research
    Clarksburg, West Virginia 26301, United States
  • Colin Bayliss Research and Teaching Unit
    Victoria Park, Western Australia 6100, Australia
  • Eastern Health Clinical School
    Box Hill, 3128, Australia
  • Royal Prince Alfred Hospital
    Camperdown, 2050, Australia
  • Menzies Centre for Population Health Research
    Hobart,, 7000, Australia
  • Optimus Clinical Research Pty. Ltd
    Kogarah, 2217, Australia
  • Coastal Joint Care
    Maroochydore, 4558, Australia
  • Westmead Cancer Care Center
    Westmead, NSW, 2145, Australia
  • Manna Research
    Vancouver, British Columbia V6J 1S3, Canada
  • Manitoba Clinic
    Winnipeg, Manitoba R3A1M3, Canada
  • Karma Clinical Trials
    Saint John's, Newfoundland and Labrador A1A 4Y3, Canada
  • Nexus Clinical Research
    St John's, Newfoundland and Labrador A1A 5E8, Canada
  • MAC Research Incorporated
    Hamilton, Ontario L8N 2B6, Canada
  • Arthur Karasik Private Practice
    Toronto, Ontario M9C 5N2, Canada
  • Manna Research
    Toronto, Ontario M9W4L6, Canada
  • Jude Rodrigues Private Practice
    Windsor, Ontario N8X 5A6, Canada
  • CHUL du CHU de Quebec
    Quebec, G1V 4G2, Canada
  • Revmatologicky ustav
    Praha 2, 128 50, Czechia
  • Revmatologicka Ambulance
    Praha 4, 140 00, Czechia
  • Revmatologicka Ambulance
    Sokolov, 356 01, Czechia
  • PV - MEDICAL, s.r.o.
    Zlin, 760 01, Czechia
  • Innomedica Medical and Research Centre
    Tallinn, EE-10117, Estonia
  • East Tallinn Central Hospital
    Tallinn, EE-11412, Estonia
  • Clinical Research Centre Ltd
    Tartu, 50106, Estonia
  • Qualiclinic kft
    Budapest, 1036, Hungary
  • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
    Debrecen, 4032, Hungary
  • MAV Korhaz es Rendelointezet Szolnok
    Szolnok, 5000, Hungary
  • Veszprém Megyei Önkormányzat Csolnoky Ferenc Kórház-Rendelöintézet
    Veszprém, 8200, Hungary
  • Waikato hospital
    Hamilton, 3204, New Zealand
  • Middlemore Clinical Trials
    Manukau, 1640, New Zealand
  • Timaru Hospital
    Timaru, 8601, New Zealand
  • Sf. Maria Clinical Hospital
    Bucharest, 011172, Romania
  • Emergency County Clinical Hospital
    Cluj-Napoca, 400006, Romania
  • Sf Apostol Andrei Emergency Clinical County Hospital
    Galati, 800578, Romania
  • SC Covamed SRL
    Sfantu Gheorghe, Covasna, 520052, Romania
  • Research Medical Complex Vashe Zdorovie
    Kazan, 420103, Russian Federation
  • Penza Regional Clinical Hospital n.a. N.N. Burdenko
    Penza, 440026, Russian Federation
  • Departmental Hospital at Smolensk Station RZhD JSC
    Smolensk, 214025, Russian Federation
  • Yaroslavl Regional Clinical Hospital
    Yaroslavl, 150062, Russian Federation
  • Hospital Universitario a Coruna
    A Coruña, 15006, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, Hospitalet De Llobregat, 08907, Spain
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital de Basurto-Osakidetza
    Bilbao, 48013, Spain
  • Hospital Universitario de Canarias
    La Laguna, 38320, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital General Carlos Haya
    Málaga, 29009, Spain
  • Corporacion Sanitaria Parc Tauli
    Sabadell, 08208, Spain
  • Hospital Clinico Universitario de Santiago
    Santiago de Compostela, 15706, Spain
09

References and documents

Publications

  • Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, Gomez-Reino JJ, Aelion JA; ACTIVE investigators. Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018 May;77(5):690-698. doi: 10.1136/annrheumdis-2017-211568. Epub 2018 Jan 17. PubMed 29343507 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Feb 2015, 17 months.

Results were first posted in Jun 2016, 1 year 3 months after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 17 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2013
First posted
Aug 20, 2013
StartActual
Sep 4, 2013
Primary completionActual
Feb 25, 2015
CompletionActual
Nov 17, 2016
Results first posted
Jun 13, 2016
Last update
May 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01925768
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 20, 2013
Start date
Sep 4, 2013
Primary completion
Feb 25, 2015
Completion
Nov 17, 2016
Results posted
Jun 13, 2016
Last update
May 12, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion